Healthcare
China hair transplant business files for Hong Kong IPO
Yonghe Medical Group, a Chinese hair healthcare specialist best known for hair transplants, is targeting a Hong Kong IPO. Its largest external shareholder is CPE, formerly CITIC Private Equity.
Australia COVID-19 nasal spray maker raises $25m
ENA Respiratory, an Australian biotech company developing a nasal spray for the prevention of COVID-19, has raised A$32 million ($25 million) with support from local venture capital investor Brandon Capital.
Chinese pharmaceutical platform Yaoshibang raises $270m
Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund.
India's Tata Digital makes healthcare, fitness investments
Tata Group’s digital unit has continued its investment spree, dipping into India’s healthcare and fitness spaces with the acquisition of telemedicine platform 1mg Technologies and a $75 million commitment to CureFit.
China gene sequencing company raises $63m
QitanTech, a gene sequencing start-up also known as Qitan Technology, has raised a RMB400 million ($63 million) Series B round led by Hillhouse Capital and a VC arm of CDH Investments.
TPG leads $220m round for China's Dingdang Health
TPG Capital has led a $220 million round for Chinese online pharmacy services provider Dingdang Health.
CITIC entities commit $94m to China's Simcere Diagnostics
SimCere Diagnostics, the diagnostics arm of Hong Kong-listed SimCere Pharmaceutical Group, has raised RMB600 million ($94 million) in Series B funding led by CITIC Securities and CITIC Medical & Health Fund.
Orchid Asia reaches $1.1b first close on Fund VIII
Orchid Asia has achieved a first close of $1.1 billion on its eighth fund, five months after launching the vehicle with a full target of $1.6 billion.
Australia's CPE exits Cell Care to US strategic
Australian middle-market private equity firm CPE has agreed to sell cord blood banking business Cell Care to Generate Life Sciences, a US-based provider of cellular services for fertility and therapeutic purposes.
China's Oceanpine raises $312m for renminbi hard-tech fund
Chinese technology and healthcare investor Oceanpine Capital has closed its Hardcore Technology Investment Fund on RMB2 billion ($312 million). LPs include government guidance funds and fund-of-funds in Suzhou, where the new vehicle is based.
China mRNA specialist Stemirna gets $200m in funding
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
Unicorn raises $450m for VC fund-of-funds
China-focused venture capital fund-of-funds Unicorn Capital Partners has closed its latest vehicle at the hard cap of $450 million. The process took six months and the fund was oversubscribed
Singapore's Heritas hits first close on Asia impact fund
Heritas Capital, a Singapore-based private equity firm sponsored by industrial conglomerate IMC Group, has reached a first close of $60 million on a pan-Asia impact investment fund.
L Catterton leads $40m Series B for Singapore's Zenyum
L Catterton has led a $40 million Series B round for Singapore’s Zenyum, a company that makes 3D-printed dental products.
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
China's Yingke closes renminbi, US dollar funds
Shanghai-based Yingke Private Equity has raised RMB10 billion ($1.57 billion) for its latest renminbi-denominated fund as well as an undisclosed sum for a third US dollar vehicle.
Vivo, Novo back Singapore's Esco Lifesciences
Vivo Capital and Novo Holdings have led a $200 million Series A round for Esco Lifesciences, a Singapore-based manufacturer of biopharma lab equipment and medical devices.
TR, Shenzhen Capital back renminbi continuation fund
TR Capital and Shenzhen Capital Group have backed the spin-out of six healthcare assets held by China focused GP Huagai Capital into a RMB800 million ($125 million) renminbi-denominated continuation fund.
Deal focus: Navis targets hospitals in the hinterlands
The Southeast Asian manager will commit up to $100 million to hospital roll-up strategy intended to address rising demand for private healthcare in Malaysia’s underserved territories
Deal focus: Novo spreads its wings in Southeast Asia
In Hummingbird Bioscience and Halodoc, Novo Holdings believes it has backed a potential global leader in hard-to-drug cancer and a likely domestic champion in telemedicine and disease management
Navis acquires Malaysia hospital developer
Navis Capital Partners has acquired a majority stake in Malaysia-based hospital developer Aurelius Healthcare for an undisclosed sum.
Lilly Asia leads $90m round for China's Duality Biologics
Lilly Asia Ventures has led a $90 million Series B round for Duality Biologics, a Chinese developer of oncology and autoimmune drugs.
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
Legend closes China healthcare continuation fund
Legend Capital has spun out the healthcare assets from two of its China venture capital funds into a continuation vehicle supported by Hamilton Lane and Coller Capital. The $270 million deal includes capital for follow-on investments.